Deutsche Bank Ag\ Kal Vista Pharmaceuticals, Inc. Transaction History

Deutsche Bank Ag\

$248 Billion
Q4 2024

A detailed history of Deutsche Bank Ag\ transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 35,841 shares of KALV stock, worth $427,224. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,841

Previous 21,918 63.52%

Holding current value

$427,224

Previous $253,000 19.76%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$8.09 - $12.5 $112,637 - $174,037	13,923 Added 63.52%	35,841 $303,000
Q3 2024 Nov 13, 2024	BUY	$9.46 - $15.39 $57,327 - $93,263	6,060 Added 38.21%	21,918 $253,000
Q2 2024 Aug 14, 2024	BUY	$10.35 - $12.49 $37,901 - $45,738	3,662 Added 30.03%	15,858 $186,000
Q1 2024 May 15, 2024	BUY	$11.07 - $16.04 $7,217 - $10,458	652 Added 5.65%	12,196 $144,000
Q4 2023 Feb 14, 2024	SELL	$7.58 - $12.25 $2,539 - $4,103	-335 Reduced 2.82%	11,544 $141,000
Q3 2023 Nov 09, 2023	BUY	$8.95 - $11.35 $22,303 - $28,284	2,492 Added 26.55%	11,879 $114,000
Q2 2023 Aug 14, 2023	SELL	$7.73 - $10.57 $44,339 - $60,629	-5,736 Reduced 37.93%	9,387 $84,000
Q1 2023 May 15, 2023	BUY	$6.3 - $8.39 $29,754 - $39,625	4,723 Added 45.41%	15,123 $118,000
Q4 2022 Feb 13, 2023	BUY	$4.2 - $14.24 $680 - $2,306	162 Added 1.58%	10,400 $70,000
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $3,890 - $6,647	-395 Reduced 3.71%	10,238 $149,000
Q2 2022 Aug 11, 2022	SELL	$8.16 - $15.1 $18,107 - $33,506	-2,219 Reduced 17.27%	10,633 $105,000
Q1 2022 May 13, 2022	SELL	$11.2 - $16.97 $13,731 - $20,805	-1,226 Reduced 8.71%	12,852 $189,000
Q4 2021 Feb 11, 2022	SELL	$12.36 - $18.28 $20,146 - $29,796	-1,630 Reduced 10.38%	14,078 $186,000
Q3 2021 Nov 04, 2021	BUY	$17.11 - $24.49 $61,886 - $88,580	3,617 Added 29.91%	15,708 $274,000
Q2 2021 Aug 11, 2021	SELL	$23.12 - $29.91 $8,878 - $11,485	-384 Reduced 3.08%	12,091 $289,000
Q1 2021 May 13, 2021	BUY	$14.69 - $42.57 $25,898 - $75,050	1,763 Added 16.46%	12,475 $320,000
Q4 2020 Feb 16, 2021	BUY	$12.88 - $19.47 $40,134 - $60,668	3,116 Added 41.02%	10,712 $203,000
Q3 2020 Nov 12, 2020	BUY	$9.83 - $13.99 $8,345 - $11,877	849 Added 12.58%	7,596 $95,000
Q2 2020 Aug 13, 2020	BUY	$6.75 - $12.89 $16,274 - $31,077	2,411 Added 55.6%	6,747 $82,000
Q1 2020 May 14, 2020	SELL	$5.8 - $18.56 $1,519 - $4,862	-262 Reduced 5.7%	4,336 $33,000
Q4 2019 Feb 14, 2020	SELL	$10.31 - $17.81 $42,879 - $74,071	-4,159 Reduced 47.49%	4,598 $81,000
Q3 2019 Nov 14, 2019	SELL	$11.6 - $21.67 $6,136 - $11,463	-529 Reduced 5.7%	8,757 $101,000
Q2 2019 Aug 14, 2019	SELL	$18.44 - $30.89 $156,758 - $262,595	-8,501 Reduced 47.79%	9,286 $204,000
Q1 2019 May 15, 2019	BUY	$16.51 - $31.1 $290,873 - $547,919	17,618 Added 10424.85%	17,787 $508,000
Q4 2018 Feb 14, 2019	SELL	$16.21 - $24.06 $128,415 - $190,603	-7,922 Reduced 97.91%	169 $3,000
Q3 2018 Dec 21, 2021	SELL	$8.0 - $22.11 $40 - $110	-5 Reduced 0.06%	8,091 $179,000
Q3 2018 Nov 14, 2018	SELL	$8.0 - $22.11 $137,056 - $378,788	-17,132 Reduced 67.91%	8,096 $179,000
Q2 2018 Apr 21, 2020	SELL	$7.79 - $9.84 $38 - $49	-5 Reduced 0.02%	25,228 $205,000
Q2 2018 Aug 14, 2018	SELL	$7.79 - $9.84 $140,313 - $177,238	-18,012 Reduced 41.65%	25,233 $204,000
Q1 2018 Oct 18, 2019	SELL	$9.22 - $12.35 $46 - $61	-5 Reduced 0.01%	43,245 $409,000
Q1 2018 May 15, 2018	SELL	$9.22 - $12.35 $375,751 - $503,311	-40,754 Reduced 48.51%	43,250 $410,000
Q4 2017 Feb 14, 2018	BUY	$6.8 - $13.54 $571,193 - $1.14 Million	83,999 Added 1679980.0%	84,004 $819,000
Q3 2017 Nov 14, 2017	BUY	$5.84 - $8.88 $29 - $44	5	5 $0

Others Institutions Holding KALV

# of Institutions

131

Shares Held

53.3M

Call Options Held

63.5K

Put Options Held

36.6K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $293M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account